Steve Cohen’s Point72 Asset Management New Position in NxStage Medical, Inc. (NASDAQ:NXTM)

Point72 Asset Management has filled a SC 13G form regarding Nxstage Medical, Inc 16.02 -0.19 -1.17%. Filing Link: 000089914015000460. Per Steve Cohen’s Point72 Asset Management’s filing, the filler now owns 5% of the Health Care-company, holding 3,163,744 shares.

NxStage Medical, Inc. (NASDAQ:NXTM) is a newly disclosed equity position for the hedge fund and the filing was required due to activity on May 29, 2015. This most probably shows Steve Cohen’s Point72 Asset Management’s confidence and optimism in the future of the company.

The hedge fund has been active in the Finance sector recently. In the fund’s latest 13F, it revealed several positions. This sector is 23% of Steve Cohen’s Point72 Asset Management’s US equities portfolio.

Nxstage Medical, Inc Hedge Funds Ownership

Latest SEC filings show 116 hedge funds and institutional investors own Nxstage Medical, Inc. The institutional ownership of the company in Q1 2015 is high, at 92.03% of the shares outstanding. They increased by 2370379 the total shares they hold. As of that quarter these institutional investors owned 58172942 shares. A total of 12 funds opened new positions in Nxstage Medical, Inc and 49 increased their holdings. There were 9 funds that closed their positions and 35 that reduced them.

7 investors have the firm in their Top 10. Some of these are: Cortina Asset Management Llc, Dafna Capital Management Llc, Oracle Investment Management Inc, Deerfield Management Co, First Light Asset Management Llc, Tamarack Capital Management Llc, Broadview Advisors Llc..

Altrinsic Global Advisors Llc is the most positive institutional investor on Nxstage Medical, Inc, with ownership of 666300 shares as of Q1 2015 for 0.25% of the fund’s portfolio. Cortina Asset Management Llc is another positive player owning 2155427 shares of the company or 1.61% of their stocks portfolio. CA Dafna Capital Management Llc have 4.87% of their stock portfolio invested in the stock for 366554. Further, Oracle Investment Management Inc disclosed it had purchased a stake worth 8.24% of the fund’s stock portfolio in the company. The NY Deerfield Management Company was also a notable investor in the firm, owning 5073050 shares. Nxstage Medical, Inc is 2.84% of the fund’s stock portfolio.

Company Profile

NxStage Medical, Inc. (NxStage)is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). The Company operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it sells and rents the System One, PureFlow SL equipment and disposable products in the home and critical care markets. In the In-Center segment, it sells of blood tubing sets and needles for hemodialysis at dialysis centers and needles for apheresis. The Company’s products include the NxStage System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.

Tagged: NASDAQ:NXTM

...